The latest research follows up on previous studies that have demonstrated CBD can reduce cravings for alcohol and cocaine in animal models.
New research from C.V. Sciences, Inc., a hemp-derived CBD company, in collaboration with the University of California, San Diego, has found further evidence that CBD could reduce nicotine dependence and withdrawal symptoms.
CV Sciences has patented a proprietary CBD and nicotine formulation for treating smokeless tobacco addiction.
The research was published in Psychopharmacology and follows up on previous studies that have demonstrated CBD can reduce cravings for alcohol and cocaine in animal models. A 2018 study published in the journal Addiction also found that CBD holds promise as a treatment for tobacco addiction.
Using an experimental medicine with 30 dependent cigarette smokers, researchers found that a single 800-mg oral dose of CBD reduced the salience and pleasantness of cigarette cues, compared with a placebo, after overnight cigarette abstinence.
“These findings suggest that cannabidiol has promise as a novel treatment for tobacco addiction,” said Dr. Tom Freeman, who helped conduct the study. “It might be particularly effective when abstinent smokers are exposed to cues that trigger relapse, such as when they are with a friend who lights a cigarette, or in a particular place they associate with smoking,” Dr. Freeman added.
Subscribe to Weekend Dispensary, a new weekly newsletter from The GrowthOp.